Few people stay on the same GLP-1 forever. A pharmacy shortage forces a substitution. An insurance formulary changes in January. A plateau prompts a conversation about trying the other molecule, or side effects prompt one about trying a gentler ramp. Whatever the reason, switching medications drops you into a few strange weeks where two drugs share your body and none of your old reference points quite apply.
Those weeks are exactly when a tracker earns its keep. Here is what actually happens during a switch, and what to write down so that you and your prescriber can see the transition clearly instead of guessing through it.
Why switches happen
Most transitions fall into a handful of stories. Supply: a medication becomes unavailable at your pharmacy and your prescriber substitutes what can actually be filled. Coverage: an insurer or employer plan prefers one brand over another, and the preferred list changes. Response: weight or glucose results have stalled, and the prescriber suggests the other molecule, most commonly a move between semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). And tolerability: persistent side effects on one product sometimes ease on another.
The reason matters for one practical purpose: it shapes what your prescriber will want to see in your log afterwards. A response-driven switch calls for clean weight trend data across the boundary. A tolerability-driven switch calls for a side effect diary that shows whether the move actually helped.
The overlap: one drug’s tail, the other’s rise
GLP-1s do not stop working when you stop injecting them. Semaglutide’s half-life is about a week, which means that weeks after your last Ozempic or Wegovy dose, a meaningful fraction is still circulating and fading slowly. Tirzepatide’s half-life is about five days, so its tail is a little shorter but still measured in weeks, not days. Meanwhile the new medication starts at the bottom of its own curve, accumulating dose by dose toward a steady state that takes roughly a month to reach.
Put those together and the transition period is a crossfade, not a cut. For the first few weeks on the new drug, what you feel is a blend: the old medication’s declining tail plus the new one’s rising level. This is worth understanding because it explains two common surprises. Appetite sometimes stays quiet through the early low doses of the new drug (the old one is still helping), and then wobbles a few weeks in as the tail runs out before the new drug has climbed. Neither means the switch failed; it is the shape of the math. The blend is also why prescribers, not calculators, own the timing: the right gap between the last old dose and the first new one depends on the doses involved, your tolerability history and the reason for the switch. Our guides to the semaglutide half-life and the tirzepatide half-life show these curves in detail.
Your ladder usually restarts
The most counterintuitive part of switching: doses do not translate. Being on 2.4 mg of Wegovy does not mean starting Zepbound at its top dose, and a milligram of semaglutide is not comparable to a milligram of tirzepatide; they are different molecules with different potencies and different ladders. Prescribers typically restart the new medication’s own titration, often at or near the bottom, and climb it on its own schedule. Sometimes the prescribing information or the clinician’s judgment supports entering partway up; that is their call to make, never a place for arithmetic of your own.
For tracking, this means your "week 3 of 4 at this step" counter starts over. Treat the switch like a new beginning in the log: new medication, new ladder, new step-week counts. Our guide to titration schedules lays out every ladder, so you can see the road ahead on the new medication before the first injection.
The schedule itself may change too. A switch is a natural moment for your shot day to move, and if the two medications run on different cadences (weekly to daily, or the reverse), the whole rhythm of your reminders changes. Update the plan in your tracker on day one, so the reminders match reality rather than the old routine.
GLP 1 Tracker AppFree on the App Store. Real titration ladders for every GLP-1, so a switch is two taps: new medication, new step.
Get the app
Side effects often make a brief comeback
Even people who sailed through months at a high dose are often surprised to feel queasy again in the first weeks on a new GLP-1. It makes sense: your body is meeting a new molecule at the start of its own ramp, and nausea on these medications is typically at its worst after dose changes before fading over weeks. The pattern usually mirrors a first titration in miniature, softer and shorter, but real.
This is the moment to lean on the side effect diary. Log effects with severity, especially in the days after each shot, and the transition writes its own report: whether the new medication is genuinely gentler, whether a particular step is the sticking point, and whether things are trending better or worse by week three. That record is precisely what your prescriber needs at the follow-up where you decide the switch worked. Our guide to tracking side effects covers how to keep that diary useful without turning it into homework.
What to log through a switch
A clean transition record has a handful of entries that take a minute in total:
- The last dose of the old medication: date, dose, and site, clearly logged. Every question about tails and timing starts here.
- The first dose of the new medication: the same, plus the step you started on.
- The gap between them, which your prescriber chose deliberately; the log preserves what actually happened, not what was planned.
- Daily basics through the crossfade: weight, water, protein, and a short appetite note. Continuity here is what makes the before-and-after comparison honest.
- Side effects with severity, as above, clustered around the new shot days.
One quiet advantage of keeping everything in a single tracker: the weight trend does not reset just because the medication did. Six months from now, the graph across the switch boundary answers the only question that matters, which is whether the change moved you forward.
Questions worth settling before the first new dose
A switch goes smoothest when the practical details are settled at the prescribing visit instead of discovered at the kitchen counter. Worth asking while you are still in the room:
- When exactly should the last dose of the old medication happen, and how long a gap before the first new one?
- Which step does the new ladder start on, and how long is each step expected to last?
- Does the shot day or the cadence change, and from which date?
- Which returning side effects are expected, and which ones would justify a call?
- What are the new medication’s late-dose rules? They differ between products, as our missed dose guide shows.
Write the answers into your tracker’s notes on the spot. Two months later, when the visit has faded, the plan will still be exactly where the doses are logged.
The takeaway
A GLP-1 switch is a crossfade between two curves, run by your prescriber, and it goes smoothest when the record is complete: last old dose, first new dose, a restarted ladder counted honestly, and a couple of weeks of extra attention to side effects and appetite. Log those, and the strange middle weeks become data instead of doubt.
Frequently asked questions
Do I start at the same dose when I switch from one GLP-1 to another?
Usually not. Semaglutide and tirzepatide are different molecules with different potencies and different ladders, so a milligram of one is not comparable to a milligram of the other. Prescribers typically restart the new medication’s own titration, often at or near the bottom, and climb it on its own schedule. Where you enter the new ladder is always your prescriber’s call, never arithmetic of your own.
Will side effects come back when I switch GLP-1 medications?
Often, briefly. Your body is meeting a new molecule at the start of its own ramp, and nausea on these medications is typically at its worst after dose changes before fading over weeks. The return usually mirrors a first titration in miniature, softer and shorter. Logging side effects with severity through those first weeks shows whether the new medication is genuinely gentler for you.
How long does the old GLP-1 stay in my system after switching?
Weeks, not days. Semaglutide’s half-life is about a week and tirzepatide’s about five days, so a meaningful fraction of the old medication is still circulating well after the last dose and fades gradually. Meanwhile the new drug climbs toward its steady state over roughly a month. The transition is a crossfade of the two curves, and the gap between the last old dose and the first new dose is timed by your prescriber.
What should I track when switching GLP-1 medications?
Five things: the last dose of the old medication (date, dose, site), the first dose of the new one plus the step it started on, the gap between them, daily basics through the transition (weight, water, protein, a short appetite note), and side effects rated for severity around the new shot days. That record turns the follow-up question of whether the switch worked into data instead of guesswork.
Can a tracker app handle a switch between GLP-1 medications?
Yes. GLP 1 Tracker App carries real titration ladders for the supported GLP-1s across weekly, daily and twice-daily cadences, so a switch means selecting the new medication and its starting step; reminders follow the new schedule and the weight trend continues across the boundary. The app records the plan your prescriber sets and never suggests what dose comes next.